Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
San Antonio Breast Cancer Symposium (SABCS)
What Differentiates Abemaciclib, Ribociclib, and Palbociclib?
SABCS 2017
Videos
Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer.
Related Items
Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Final Results of NeoMONARCH: A Phase 2 Neoadjuvant Study of Abemaciclib in Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
A Phase 1b Study of Abemaciclib plus Pembrolizumab for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
US Treatment Patterns for Young Women with HR-Positive, HER2-Negative Metastatic Breast Cancer in the Era of CDK4/6 Inhibitors
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Phase 1-2 Trial of Pembrolizumab and Either Doxorubicin or an Aromatase Inhibitor for Triple-Negative or HR-Positive Metastatic Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Abemaciclib plus Standard Adjuvant ET versus Standard Adjuvant ET Alone in High-Risk Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
The Synergistic Antitumor Activity of Entinostat (MS-275) in Combination with Palbociclib (PD 0332991) in ER-Positive and TN Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Abemaciclib for the Treatment of Brain Metastases Secondary to HR-Positive Breast Cancer
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Phase 2 Study of the Feasibility and Safety of Radium-223 Dichloride plus Hormonal Therapy and Denosumab for the Treatment of HR-Positive Breast Cancer with Bone-Dominant Metastasis
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
The Benefit of Abemaciclib in Prognostic Subgroups: An Exploratory Analysis of Combined Data from MONARCH 2 and 3
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2017
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us